Home/Catalog/SaaS & AI Change Control: Keep Your Validated Systems Under Control Without Revalidating Everything
← Back to Catalog
Live WebinarNew

SaaS & AI Change Control: Keep Your Validated Systems Under Control Without Revalidating Everything

Learn how to manage SaaS updates, configuration drift, vendor releases and AI model changes using risk-based change control—without turning every update into a full revalidation project.

0(0 reviews)
1.5 hoursFriday, October 2, 2026
Carolyn Troiano

Instructor

Carolyn Troiano

FDA Compliance & Computer System Validation Consultant

What You'll Learn

Recognize the different ways SaaS and AI systems can change after validation.
Identify configuration drift before it creates an uncontrolled change to the validated state.
Assess the GxP impact of vendor releases, patches, configuration changes and system upgrades.
Distinguish vendor-controlled, customer-controlled and shared-responsibility changes.
Determine when existing supplier evidence can contribute to your change assessment.
Decide when documentation, targeted testing, regression testing, expanded testing or revalidation is appropriate.
Evaluate AI model updates, retraining and performance changes using a risk-based lifecycle approach.
Control changes to APIs, integrations and connected systems.
Build scalable change-control processes that prevent unnecessary validation backlogs.
Demonstrate continued control of computerized systems with inspection-ready evidence.

About This Event

A practical guide to SaaS updates, configuration drift, AI model changes, testing decisions and inspection-ready change control. YOUR SAAS SYSTEM CHANGED. IS YOUR VALIDATION STILL DEFENSIBLE? A vendor releases a new version. A configuration changes. An API is updated. A security patch is deployed. An AI model is retrained. A supplier changes functionality. Does every one of these changes require revalidation? No. But ignoring the change isn't an acceptable strategy either. The real challenge is knowing what changed, what risk changed, what evidence already exists, and what level of testing or assurance is actually justified. This practical masterclass gives QA, validation, IT and AI governance professionals a risk-based framework for managing continuous change in SaaS and AI-enabled systems while maintaining compliance, data integrity and inspection readiness. ABOUT THIS EVENT SaaS and AI-enabled systems are changing faster than traditional validation cycles were designed to handle. Cloud applications receive frequent vendor releases. Security patches and infrastructure changes can occur outside the organization's direct control. Configurations evolve. APIs and integrations change. AI models may be updated, retrained or replaced. For regulated organizations, this creates a difficult question: how do you maintain a validated and controlled state without treating every technology change as a full revalidation project? This practical webinar provides a risk-based approach to managing continuous change in SaaS and AI-enabled systems. Participants will learn how to identify configuration drift, assess vendor and customer responsibilities, evaluate the GxP impact of software releases, determine when targeted testing or regression testing is appropriate, and establish defensible criteria for when revalidation is actually necessary. The session also addresses AI-specific changes, including model updates, retraining, performance monitoring, training and test data, intended use and human oversight. Rather than choosing between "revalidate everything" and "trust the vendor," participants will learn a structured approach: identify the change, assess the impact, evaluate the risk, review existing evidence, determine the appropriate assurance, document the decision and maintain the validated state. The webinar draws on current risk-based computerized-system practices, including FDA Computer Software Assurance concepts, ISPE GAMP 5 Second Edition, the ISPE GAMP Guide: Artificial Intelligence, and emerging international expectations for cloud and AI-enabled computerized systems. The objective is simple: keep your SaaS and AI systems under control as they change, without creating unnecessary validation workload or leaving compliance gaps. WHY THIS WEBINAR NOW Software no longer waits for your validation cycle. Modern regulated environments increasingly depend on SaaS platforms, cloud services, integrations and AI-enabled applications. These systems can change through vendor releases, security patches, configuration changes, API updates, infrastructure changes, new integrations, AI model updates, retraining, and changes to data or workflows. Traditional approaches can create two opposite risks. Too little control: changes occur without adequate assessment, testing, documentation or oversight. Too much control: every change becomes a major validation activity, creating backlogs, delaying improvements and consuming resources that could be focused on higher-risk changes. The practical answer is risk-based change control. The objective is not fewer controls. The objective is the right controls for the risk. WHAT WOULD YOU DO? A vendor sends you this email: "Our platform will be upgraded to the latest version next weekend." What do you do? A. Revalidate the entire system. B. Do nothing because the vendor performed the testing. C. Open a change assessment and determine the appropriate level of assurance. The webinar teaches participants how to get to C and, more importantly, how to document why. THE CHANGE-IMPACT DECISION FRAMEWORK Ask seven questions: 1. What changed? 2. Why did it change? 3. What intended use could be affected? 4. What GxP functionality could be affected? 5. What could go wrong? 6. What evidence already exists? 7. What additional assurance is justified? Then arrive at one of five outcomes: (1) document the assessment, no additional testing justified; (2) update documentation, where procedures, configuration or specifications require revision; (3) targeted verification of the affected functionality; (4) regression testing of affected critical functionality and dependencies; (5) revalidation, when the change is significant enough to invalidate or materially alter existing assurance. The SaaS & AI Change Decision Matrix classifies every change (vendor patch: does critical functionality change? new feature: does intended use change? configuration: does GxP behavior change? API: does data flow change? infrastructure: does the regulated service change? AI model: does model behavior or performance change? retraining: does the evidence remain applicable? new integration: does risk extend downstream?) and follows one path: assess, classify, test, approve, implement, verify, document. WHEN DO YOU REALLY NEED REVALIDATION? Assess intended use, GxP criticality, data integrity, critical functionality, product quality, patient safety, system architecture, integration impact, supplier evidence, previous validation evidence and residual risk. Revalidation is a risk-based decision, not an automatic response to every software release. CONFIGURATION DRIFT: THE HIDDEN COMPLIANCE RISK Your validated system was approved with six user roles, three approval workflows, two interfaces and defined notification rules. Six months later one role was added, a workflow changed, an interface was modified and a notification rule was disabled. Nobody changed the core software version. Is the system still the same validated system? Topics: configuration baseline, production versus test environments, privileged changes, administrator access, configuration monitoring, periodic review, documentation and change ownership. AI CHANGES ARE DIFFERENT Model version (did the underlying model change?), training (was the model retrained?), data (did training or test data change?), performance (did performance metrics change?), intended use (is the AI now used for something different?), output (could outputs affect a GxP decision?), monitoring (how will the organization know if performance changes?) and human oversight (when must a person review or override the output?). Case study, the vendor changed your AI model overnight: your company uses an AI-enabled SaaS application, and the vendor announces "We've upgraded to our newest AI model for improved performance." You did not initiate the change. Is this a change? Who owns the assessment? Did intended use change? What evidence does the vendor provide? What performance evidence should you request? What should be tested? What should be monitored? Does the change affect your validated state? Do you need revalidation? PRACTICAL CASE STUDIES Case-based learning using scenarios: a SaaS vendor releases a major update; an administrator changes a validated workflow; a security patch changes system behavior; an API version changes; an AI model is retrained; a vendor changes the underlying AI model; production configuration drifts from the validated configuration. For each: what changed, what is the risk, what evidence exists, what should be tested, is revalidation necessary? BUILD AN INSPECTION-READY CHANGE-CONTROL PROGRAM Be able to show what changed, who assessed it, what the risk was, what evidence was reviewed, why this testing level was selected, who approved it, what was implemented and whether the system was still under control. LEARNING OBJECTIVES At the conclusion of this webinar, participants should be able to: 1. Explain why SaaS and AI systems require a different approach to maintaining the validated state than static, infrequently updated systems. 2. Identify configuration drift and assess its potential effect on GxP-controlled processes. 3. Assess the impact of vendor releases, patches, configuration changes, integrations and infrastructure changes. 4. Apply a structured, risk-based framework for determining the appropriate level of change assessment. 5. Determine when documentation, targeted verification, regression testing or revalidation is justified. 6. Evaluate supplier testing and assurance evidence as part of a change-control decision. 7. Assess AI model updates, retraining and performance changes throughout the AI lifecycle. 8. Establish appropriate controls for APIs, integrations and connected platforms. 9. Reduce unnecessary validation workload while maintaining appropriate compliance controls. 10. Demonstrate continued control of SaaS and AI-enabled systems using traceable, inspection-ready evidence. Regulatory note: regulatory requirements vary by product, system, jurisdiction and intended use. Participants should evaluate the requirements applicable to their specific environment.

Curriculum

Module 1: Why Continuous Change Is Breaking Traditional Validation Cycles
10 min
Module 2: What Actually Changes in SaaS Systems?
10 min
Module 3: Configuration Drift: Finding the Hidden Changes
12 min
Module 4: The Change-Impact Decision Framework
15 min
Module 5: When Do You Need Testing or Revalidation?
13 min
Module 6: AI Model Changes, Retraining & Ongoing Monitoring
12 min
Module 7: Vendor, Cloud & Integration Changes
10 min
Module 8: Building an Inspection-Ready Change-Control Program
8 min

Requirements

  • Intermediate-level familiarity with GxP, computerized systems, quality systems, validation or change control is recommended.

Who Should Attend

This webinar is designed for professionals responsible for keeping cloud, SaaS and AI-enabled computerized systems compliant throughout their operational lifecycle. Quality and validation: Quality Assurance professionals, CSV professionals, CSA practitioners, Validation Managers, Validation Engineers, Quality Systems professionals, Data Integrity professionals, Computerized System Quality professionals. IT and digital: GxP IT professionals, IT Quality professionals, SaaS system owners, Application owners, Cloud transformation leaders, Digital transformation teams, IT change managers, Integration/API owners. AI: AI governance teams, AI/ML quality professionals, AI validation professionals, Digital quality leaders, AI risk-management professionals. Compliance and regulatory: Compliance Managers, Regulatory Affairs professionals, Internal auditors, Supplier quality professionals, Vendor-management teams, GxP consultants. Organizations: particularly relevant to pharmaceutical, biotechnology, medical-device, clinical-research, laboratory, CDMO, CRO and life-science technology organizations using cloud, SaaS or AI-enabled systems.

Areas Covered

Continuous SaaS Change: vendor releases; software updates; security patches; new functionality; cloud infrastructure changes; maintaining the validated state
Configuration Drift: configuration baselines; production versus test environments; user roles and permissions; workflow changes; business rules; privileged changes; detecting undocumented drift
Risk-Based Change Control: GxP impact assessment; intended use; critical functionality; data integrity; product quality; patient safety; residual risk; proportionate assurance
Testing & Revalidation: documentation-only changes; targeted verification; regression testing; integration testing; expanded testing; revalidation triggers; evidence-based decisions
SaaS Vendor Management: release notes; supplier testing; vendor assurance evidence; change notifications; shared responsibility; supplier oversight; quality agreements
AI System Changes: model version changes; retraining; training-data changes; test-data considerations; performance metrics; model monitoring; model drift; intended-use changes; human oversight; AI lifecycle control
APIs & Integrations: interface changes; middleware; data mappings; connected systems; downstream impact; integration testing
Backlog Management: change categorization; standard assessment pathways; predefined testing strategies; supplier evidence; risk-based prioritization; change-control metrics; validation workload management
Inspection Readiness: traceability; change records; impact assessments; testing evidence; approval records; configuration history; validation status; continued control

Meet Your Instructor

Carolyn Troiano

Carolyn Troiano

FDA Compliance & Computer System Validation Consultant

Carolyn Troiano has more than 45 years of experience in computer system validation in the pharmaceutical, medical device, biotechnology, tobacco, and other FDA-regulated industries. She is currently an independent consultant, advising companies on FDA compliance, Computer System Validation (CSV), and large-scale IT system implementation projects. Carolyn participated in the FDA/Industry Partnership to develop 21 CFR Part 11, the FDA's Guidance for Electronic Records and Electronic Signatures. During her career she has provided training on CSV, 21 CFR Part 11, Data Integrity, and many other compliance topics of interest to the life science industries.

45+ Years CSV Experience21 CFR Part 11 Co-DeveloperIndependent FDA Consultant
Quantity
1

Single: 1 Attendee

$240.00
Buy Now
Secure payment via Stripe
Certificate of completion

Event Details

Format

Live Webinar

Duration

1.5 hours

Certificate

Included

Date

Friday, October 2, 2026

Related Events

Digital Quality Metrics and AI/ML Analytics: Building a Continuous-Improvement Framework that Aligns with Regulatory Expectations
Live WebinarNew
Regulatory & ComplianceCertificate

Digital Quality Metrics and AI/ML Analytics: Building a Continuous-Improvement Framework that Aligns with Regulatory Expectations

Learn how AI/ML and real-time digital quality metrics build a continuous-improvement framework aligned with FDA regulatory expectations, 21 CFR Part 11, and GAMP®5.

Carolyn TroianoCarolyn Troiano
1.5 hoursJun 18, 2026
4.9
from$145.00
View Details
AI in GMP: What the FDA Is Already Expecting - Before You Ask
Live WebinarNew-24%
Regulatory & ComplianceCertificate

AI in GMP: What the FDA Is Already Expecting - Before You Ask

FDA already expects GMP compliance for AI systems. Learn how existing validation, data integrity, and oversight rules apply—before regulators come calling.

Dr. Ginette CollazoDr. Ginette Collazo
1.5 hoursJun 30, 2026
4.8
from$190.00$250.00
View Details
HPLC Analytical Method Development and Validation
Live WebinarNew
Regulatory & ComplianceCertificate

HPLC Analytical Method Development and Validation

Master HPLC instrument and method validation to meet US EPA and FDA requirements for pharmaceutical analysis.

Dr. John C. FetzerDr. John C. Fetzer
1 hourJun 17, 2026
4.8
from$145.00
View Details